Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Biomarkers in Chronic Obstructive Pulmonary Disease: Emerging Roles of Eosinophils and Procalcitonin

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Immunoregulation of Neutrophil Extracellular Trap Formation by Endothelial-Derived p33 (gC1q Receptor)

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. In Memoriam: A Tribute to Professor Niels Borregaard

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Lectin Complement Pathway in Patients with Necrotizing Soft Tissue Infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Staphylococcal Proteases Aid in Evasion of the Human Complement System

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Treatment Response Biomarkers in Asthma and COPD

    Research output: Contribution to journalReviewResearchpeer-review

  2. Alfa-1 Antitrypsinmangel

    Research output: Contribution to journalReviewResearchpeer-review

  3. Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Corticosteroid Resistance in Smokers-A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Antibiotics can improve the prognosis in patients with exacerbation of chronic obstructive pulmonary disease. However, the overuse of antibiotics can carry serious adverse effects for patients (gastrointestinal infections) and for society (bacterial resistance). Likewise, systemic corticosteroids may also help these patients, but also carries severe adverse effects like osteoporosis, muscle loss, and diabetes, in many patients. Whenever safe methods exist to reduce these two treatment modalities, they should be implemented. The blood biomarkers procalcitonin and the fraction of leukocytes known as eosinophil granulocytes have been proven in randomized controlled trials (RCTs), to effectively, significantly, and substantially assist in reducing the use of these two potent, yet toxic medication types. In this review, the background and main clinical results are discussed, explaining the rationale for biomarker-guided clinical decisions. Also, the main expected effects, their sizes, and importantly the limitations to such a strategy are described. Clinical evidence is prioritized with main weight on RCTs and meta-analyses of these and regarding outcomes, and focus is set on the safety of such a biomarker-guided strategy, as well as the effects on medicine reduction. In an epoch of increasing demands to physicians from patients and politicians to cure and reduce symptoms, the Hippocratic phrase of "primum non nocere" or "first, do no harm" seems more than ever of contemporary importance.

Original languageEnglish
JournalJournal of Innate Immunity
Pages (from-to)1-9
Number of pages9
ISSN1662-811X
DOIs
Publication statusE-pub ahead of print - 24 Aug 2021

    Research areas

  • Biomarker, Blood eosinophils, Procalcitonin

ID: 67537735